Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Antenatal Urine Samples Screened for Chlamydia

By LabMedica International staff writers
Posted on 19 Apr 2011
Urine samples from pregnant women have been successfully screened to identify those infected with Chlamydia trachomatis.

The urine screening was conducted using a commercial molecular assay utilizing target capture for the in vitro qualitative detection and differentiation of ribosomal RNA (rRNA) of C. More...
trachomatis and Neisseria gonorrhoeae.

Scientists at University of Texas Southwestern Medical Center, (Dallas, TX, USA), tested a total of 2,018 pregnant women whose mean age was 26.9 years old, and of whom 84% were Hispanic. For four months, all women who were seen at a group of family planning and obstetric complication clinics in the area and who were between 35 and 37 weeks pregnant were tested. Both urine samples and endocervical secretions were assayed.

All samples were analyzed using the Aptima Combo 2 Assay, which is a target amplification nucleic acid probe test. The prevalence of Chlamydia according to tests of cervical secretions was 4.3% compared to 4.1% using urine sampling. The results from the two samplings were considered to be almost perfectly concordant. Sensitivity of urine screening was 96.5% relative to endocervical screening where the 95% confidence interval (CI) was 90.1% to 99.3%, with a relative specificity of 100%.

Urine screening for Chlamydia has shown to be accurate in male and nonpregnant female populations using Aptima Combo 2 Assay (Gen-Probe Inc.; San Diego, CA, USA). However, the scientists were uncertain that would translate to effectiveness in pregnant women. Their concern was that pregnant women might have amplification inhibitors not present in the nonpregnant population leading to nucleic acid amplification tests being less sensitive when performed on urine as compared with cervical specimens. However, this proved not to be the case.

Scott W. Roberts, MD, lead author of the study, said, "Removing the need for a speculum examination with its potential benefits in costs and respect for patients' desires has led us to use urine nucleic acid amplification testing for our C. trachomatis screening in all pregnant women." Urine sampling is also considerably cheaper than endocervical sampling, and scores points with patients who would rather not undergo an invasive exam. Chlamydia trachomatis is the most common bacterial sexually transmitted infection in the US. This disease disproportionately affects adolescent minority women, and untreated infection can lead to lasting reproductive tract morbidity. The study was published in the April 2011, edition of Obstetrics & Gynecology.

Related Links:
University of Texas Southwestern Medical Center
Gen-Probe Incorporated


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.